Esco Aster is a vertically-integrated contract research (CRO), contract development and manufacturing organization (CDMO) founded and deeply rooted by scientists enabling fellow scientists to translate their benchwork into life-saving diagnostics, medicines, therapies, cosmeceuticals, and cellular agriculture, at affordable prices for self-sufficiency of the country.
We make complex manufacturing simple via our proprietary best-in-class continuous manufacturing platforms providing a reliable and linearly scalable outcome with a track record of being used in 7 commercial human and animal health vaccines.
We continuously invest in meeting unmet clinical needs by unlocking manufacturing bottlenecks for current and new platform modalities.
Together, we are working on an interconnected one health approach to bring your next molecule into the clinic and life.
Join us for the world we are making redefining medicine for the current and future generations to come.
One World. One Health.
Esco Aster provides variety of products and services based on best-in-class manufacturing platforms with focus on new modalities.
We aim to provide the highest yield lowest cost with linearly scalable quality to better promote healthcare access especially in the developing world, lower middle income countries.
Our cGMP-compliant cell bank can preserve a large volume of cell lines, microbial cells, and other biologics for the manufacture of commercially available therapeutics.
We ensure that all samples collected either on the field or on our biobank are carefully processed and transported using the best techniques for preservation.
We take part on several preclinical to clinical testing to determine efficacy of medical drugs and substances.
Our dedicated scientist can serve as your partner from lead optimization to commercialization for your next advanced therapy.
Apart from process equipment and turnkey facilities, we offer process development to support client's specific needs and requirements for cell culture process development and optimization. This includes cell culture medium optimization, seed preparation process development, and system layout and process integration.
We are able to provide fast, efficient and robust vaccine technology transfer with single-use solutions, predictive process control, process scale up/scale down, complexity reduction, and process validation.
Our Adherent Cell Tide Motion® Platform forms the core of our process development (PD) / Clinical Trial Material (CTM) which is translational bridge to accelerate clinical/investigational medicinal products from bench to good laboratory practice (GLP), Phase 1 / 2 clinical trial material, intermediates and Phase 3 bridging studies when converting from roller bottles, microcarriers or multilayer 2D planar cultureware into Adherent Cell Tide Motion® Platform which is linearly scalable to commercial scale.
Learn more about our COGS targets from our different manufacturing platforms!EXPLORE
Esco Aster is one of the earliest responders to Singapore COVID-19 self sufficiency across Diagnostics, Therapeutics and Vaccines.
See more on our dedicated COVID-19 page for our end to end trace, test and treat platforms. We are providing a variety of biopharma, bioscience to cell lines, drug substances and drug products as well.
Esco Aster operates on dedicated sites based on our applications of our manufacturing platforms, each site has dedicated scientists working on specific modalities. Esco Aster will continue to scale up with our collaborators and partners for future commercial expansion in Singapore or as Internal Tech Transfer to client choice of country. Facilities and applications are:
Esco AsterTide PD-Phase 2 CTM (Cells/Viruses/EVs)
Blk 67 Ayer Rajah Crescent Singapore 139950
Esco AsterMavors Cellular Agriculture and Alternative Proteins (Food)
Blk 71 Ayer Rajah Crescent Singapore 139951
Esco Aster Fermentation (Plasmids)
21 Changi South Street 1 Singapore 486777
See where we are at in our product development pipeline! These consist of our internal and international co-development collaborations with specific focus on vaccines, cell therapy, new modalities for oncology, rare/orphan drugs, genetic diseases.
See our different modes of How We Work.Explore